
HURA Stock Forecast & Price Target
HURA Analyst Ratings
Bulls say
TuHURA Biosciences Inc. is advancing its personalized cancer vaccine candidate, IFx-2.0, into a critical Phase 3 registration trial, demonstrating significant progress in its development pipeline. The company’s strategic focus on overcoming resistance to established cancer therapies, particularly through the combination of IFx-2.0 and Keytruda, positions it favorably within the immuno-oncology market. With the Phase 3 trial's initiation, TuHURA is poised to capitalize on increasing market demand for innovative cancer treatments, bolstering its potential for revenue generation and long-term growth.
Bears say
The financial outlook for TuHURA Biosciences appears concerning, as the company reported a net loss of $0.15 per share for 1Q25, which aligns closely with prior estimates but indicates sustained financial losses. Furthermore, the company faces significant risks including potential negative clinical results for its lead candidate, IFx-2.0, delays in progressing its pipeline, and challenges in securing timely regulatory approvals. Coupled with competitive pressures in the immuno-oncology space and the risk of long-term dilution, these factors contribute to an overall negative outlook for the company's stock performance.
This aggregate rating is based on analysts' research of TuHURA Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
HURA Analyst Forecast & Price Prediction
Start investing in HURA
Order type
Buy in
Order amount
Est. shares
0 shares